Reports Q1 revenue $5M, consensus $4M. The company said, “Surrozen (SRZN) remains focused on advancing a new generation of ophthalmology therapeutics that are built on a foundation of Wnt pathway biology. Surrozen’s pipeline leverages its Wnt biology expertise and antibody technologies to develop therapeutics targeting ophthalmic diseases with significant unmet medical needs.”
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SRZN:
- Surrozen management to meet with Cantor
- Surrozen: Buy Rating Reiterated as Analyst Highlights Wnt-Targeted Ophthalmology Strategy and Maintains $37 Price Target
- Surrozen initiated with a Buy at TD Cowen
- Surrozen price target raised to $36 from $32 at H.C. Wainwright
- Surrozen files $200M mixed securities shelf